Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

NCT04922008 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

356

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: capecitabine and trastuzumab
DRUG: vinorelbine and trastuzumab

Sponsor

Fudan University